Sedia Biosciences Corporation

Beaverton, OR

UEI
LB3AM53JKK33
CAGE
5UEH4
Primary NAICS
325413 In-Vitro Diagnostic Substance Manufacturing
SAM.gov registration
Expired

Company facts

Self-certified in SAM.gov
  • For Profit Organization
  • Manufacturer of Goods
Entity structure
Corporate Entity (Not Tax Exempt)
Corporate family
SAM.gov registration date
Physical address
9590 SW Gemini Dr #120, Beaverton, OR 97008, USA
Website
sediabio.com
Founded
2009
Employees
11-50
Estimated annual revenue
$1M-$10M
Industry
  1. Health Care
  2. Health Care Equipment & Services
  3. Health Care Providers & Services
SIC code
38 Instruments & Related Products

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Contract obligations by fiscal year

Fiscal year Obligated
FY2027 To date $0
FY2026 $0
FY2025 $0
FY2024 $0
FY2023 $4,313

Contract awards

Award Agency Obligated Awarded
Lab supplies and equipment - sedia rapid recency kits 75D30123P17526 CDC Pittsburgh $82,263
Lab supplies - sedia asante rapid recency assay kits 75D30120P09529 CDC Pittsburgh $119,155
Sedia biosciences lab supplies 75D30119P05114 CDC Pittsburgh $149,825
Sedia lab supply 75D30118P03105 CDC Pittsburgh $0
Asante rapid recency kits and reader 75D30118P00792 CDC Pittsburgh $112,060

Latest 5 listed here. See the rest on GovTribe.

Grant awards

Similar vendors

About the company

Sedia Biosciences Corporation, doing business as Sedia Biosciences Corp, is a privately held medical device and diagnostics company that provides laboratory supplies and equipment to support disease monitoring and prevention programs. Through federal contract awards, the company has provided rapid HIV recency assay kits, laboratory reagents, and related equipment to the Centers for Disease Control and Prevention (CDC) and prime contractors supporting CDC programs.

Specifically, Sedia Biosciences Corp has been awarded CDC purchase orders totaling over $350,000 to provide rapid recency kits, assay kits, and other laboratory supplies delivered to CDC facilities in Pittsburgh, Pennsylvania. These firm fixed price awards, made between 2019-2023, support CDC disease surveillance and prevention initiatives domestically. Additionally, in 2020 Sedia was a subcontractor to Chemonics International Inc. under a CDC task order to supply HIV-1 rapid recency assays for CDC programs in Rwanda. No set aside designations were associated with these awards to Sedia Biosciences Corp.

SBA capabilities narrative

Sedia is a leader in the development of novel in-vitro diagnostic assays using alternative fluid specimens (e.g. oral fluid, urine) for disease detection. Sedia is also the leading manufacturer of HIV incidence type assays.

Quick answers

Is Sedia Biosciences Corporation registered in SAM.gov?

Sedia Biosciences Corporation's SAM.gov registration expired on August 27, 2026.

How much has Sedia Biosciences Corporation received in federal contracts?

Federal contracts obligated $4,313 to Sedia Biosciences Corporation in fiscal years 2023 through 2027.

What is Sedia Biosciences Corporation's most recent federal award?

Sedia Biosciences Corporation's most recent federal contract award is Lab supplies and equipment - sedia rapid recency kits (75D30123P17526), from CDC Pittsburgh, on September 15, 2023.

On GovTribe

See Sedia Biosciences Corporation's full federal record

  • Federal contract awards
  • Federal grant awards
  • Subcontracting relationships
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors